SCHEMBL6485141

SCHEMBL6485141

Nc1n[nH]c2cc(-c3cccc(O)c3)ccc12

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDPK1 O15530 7/20 0.71
JAK2 O60674 4/20 0.71
CHEK1 O14757 1/20 0.59
AAK1 Q2M2I8 1/20 0.55
CDK4 P11802 1/20 0.55
CCNA2 P20248 1/20 0.55
JAK1 P23458 1/20 0.55
CCND1 P24385 1/20 0.55
CDK2 P24941 1/20 0.55
TYK2 P29597 1/20 0.55
CCND3 P30281 1/20 0.55
JAK3 P52333 1/20 0.55
AURKA O14965 1/20 0.55
TGFBR1 P36897 1/20 0.55
AURKB Q96GD4 1/20 0.55
GSK3B P49841 1/20 0.54
FGFR1 P11362 3/20 0.54
FGFR2 P21802 3/20 0.54
FGFR3 P22607 2/20 0.53
HSP90AB1 P08238 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10213901 0.87 JAK2 (0.71) PDPK1JAK2CHEK1JAK1CDK2
SCHEMBL3359710 0.85 FGFR1 (0.72) PDPK1JAK2CHEK1AAK1CDK2
SCHEMBL12907253 0.83 PDPK1 (1.00) PDPK1JAK2AAK1CDK2JAK3
SCHEMBL12907241 0.83 JAK2 (1.00) PDPK1JAK2CHEK1CDK2JAK3
SCHEMBL3361070 0.83 JAK2 (1.00) PDPK1JAK2CHEK1CDK2JAK3
SCHEMBL12907435 0.83 CHEK1 (0.58) PDPK1JAK2CHEK1AAK1CDK4
SCHEMBL10130804 0.81 PDPK1 (0.61) PDPK1JAK2CDK2JAK3AURKA
SCHEMBL4491663 0.81 PDPK1 (0.71) PDPK1JAK2CHEK1CDK4CCNA2
SCHEMBL4494112 0.81 JAK2 (0.77) PDPK1JAK2AURKATGFBR1AURKB
SCHEMBL4497038 0.81 PDPK1 (0.71) PDPK1JAK2AURKATGFBR1AURKB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101962365-A Aminoindazole derivatives as protein-kinase inhibitors AVENTIS PHARMA SA 2011-02-02 CN claimed
US-6949579-B2 Aminoindazole derivatives and intermediates, preparation thereof, and pharmaceutical compositions thereof AVENTIS PHARMA S.A. (FR) 2005-09-27 US claimed
CN-1656078-A Aminoindazole derivatives as protein kinase inhibitors AVENTIS PHARMA SA (FR) 2005-08-17 CN claimed
EP-1487804-B1 AMINOINDAZOLE DERIVATIVES AS PROTEIN-KINASE INHIBITORS AVENTIS PHARMA SA (FR) 2014-02-26 EP disclosed
CN-101962365-A Aminoindazole derivatives as protein-kinase inhibitors AVENTIS PHARMA SA 2011-02-02 CN disclosed
US-7872039-B2 N-3-chlorobenzyl-3-amino-1H-indazole-5-carboxamide; 3-aminoindazoles; glucocorticoid-depedent kinase (SGK) inhibitors; SGK-induced diseases; diabetes, obesity, metabolic syndrome (dyslipidaemia), systemic and pulmonary hypertonia, cardiovascular diseases and renal diseases, fibrosis; inflammatory agents MERCK PATENT GESELLSCHAFT (DE) 2011-01-18 US disclosed
US-7872039-B2 N-3-chlorobenzyl-3-amino-1H-indazole-5-carboxamide; 3-aminoindazoles; glucocorticoid-depedent kinase (SGK) inhibitors; SGK-induced diseases; diabetes, obesity, metabolic syndrome (dyslipidaemia), systemic and pulmonary hypertonia, cardiovascular diseases and renal diseases, fibrosis; inflammatory agents MERCK PATENT GESELLSCHAFT (DE) 2011-01-18 US disclosed
EP-1765788-B1 3-AMINOINDAZOLE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF SGK-ASSOCIATED DISEASES MERCK PATENT GMBH (DE) 2009-06-03 EP disclosed
US-20070232620-A1 3-Aminoindazoles MERCK PATENT GMBH (DE) 2007-10-04 US disclosed
US-20070232620-A1 3-Aminoindazoles MERCK PATENT GMBH (DE) 2007-10-04 US disclosed
US-6949579-B2 Aminoindazole derivatives and intermediates, preparation thereof, and pharmaceutical compositions thereof AVENTIS PHARMA S.A. (FR) 2005-09-27 US disclosed
CN-1656078-A Aminoindazole derivatives as protein kinase inhibitors AVENTIS PHARMA SA (FR) 2005-08-17 CN disclosed
US-20040014802-A1 Aminoindazole derivatives and intermediates, preparation thereof, and pharmaceutical compositions thereof AVENTIS PHARMA S.A. (FR) 2004-01-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040014802-A1 Aminoindazole derivatives and intermediates, preparation thereof, and pharmaceutical compositions thereof CYP2C8, NR0B2, NR2C2 PDPK1 4495/4885JAK2 1774/4885CHEK1 3766/4885
US-20070232620-A1 3-Aminoindazoles SGK3, SGK1, SGK2 PDPK1 118/4885JAK2 562/4885CHEK1 1306/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.